<DOC>
	<DOCNO>NCT00489905</DOCNO>
	<brief_summary>The purpose study assess effect zoledronic acid bone mineral density prostatic cancer patient currently receive androgen deprivation therapy .</brief_summary>
	<brief_title>Study Evaluation Zoledronic Acid Prevent Bone Loss Men Receiving Androgen Deprivation Therapy Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Prostate cancer patient age 5080 ADT . Baseline BMD 2 standard deviation ( SD ) mean among young adult . Patients renal liver problem , calcium bisphosphonate therapy within six month enrol study . Patients : Serum creatinine level &gt; 212 Âµmol/L ( 2.4 mg/dL ) . Creatinine clearance &lt; 50 ml/min . WBC &lt; 4.0x109/L , Hgb &lt; 10 g/dL , platelet &lt; 140x109/L . Patients know hypersensitivity bisphosphonates . Patients history disease influence bone metabolism , Page 's disease bone , primary hyperparathyroidism osteoporosis .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>bone mineral density</keyword>
</DOC>